Precision Diagnosis and Tolerance Induction in Children With Immediate-type Wheat Allergy
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 72
- 试验地点
- 2
- 主要终点
- Wheat-allergic patients who develop sustained unresponsiveness to wheat after oral immunotherapy
研究概览
简要总结
IgE-mediated wheat allergy is a growing allergy problem in children, and affected children can predict with immediate-type allergic reactions to the extent of anaphylactic shock. Current diagnostic methods based on crude wheat extract are inaccurate and unreliable. Besides, these children are managed by a passive "wait-and-see" approach that reflect the natural history of wheat allergy. Nonetheless, a significant proportion of wheat-allergic children have persistent disease until school-age and adolescence. There is an unmet need for designing effective and safe immunotherapeutic strategy for wheat allergy. This study aims to investigate performance of allergy tests based on crude wheat and wheat allergens as measured using both quantitative and functional IgE-based assays for diagnosing IgE-mediated wheat allergy; and to compare efficacy and safety of different dosages of wheat oral immunotherapy (OIT) for treating these paediatric patients. For the initial part, this study will recruit children with immediate-onset adverse reactions after wheat ingestion for different allergy tests, with their wheat allergy ascertained by the gold-standard double-blind, placebo-controlled food challenge. The investigators will then recruit the wheat-allergic children into a randomized, double-blind, parallel-group clinical trial with low-dose and standard-dose wheat OIT for 12 months. The main outcomes include the diagnostic performance of different conventional and novel allergy tests for challenge-confirmed wheat allergy and the rates of desensitization and sustained unresponsiveness achieved by the two dosing regimens of wheat OIT.
详细描述
Study Background
Wheat (Triticum aestivum) is one of the foods with wide global consumption and one of the Big 8 foods causing allergy. IgE-mediated wheat allergy tends to be associated with severe anaphylactic reactions when compared with cow's milk, egg and soy. Wheat proteins can be classified into four fractions, namely albumin, globulin, gliadin and glutenin, according to their solubility. Among these proteins, Nilsson reported that omega-5 gliadin had the highest specificity to diagnose IgE-mediated wheat allergy. Wheat allergic children also showed IgE response to glutenins, alpha-, beta-, gamma-gliadins, and alpha amylase inhibitors. Depending on ethnicity and cooking practices, the major wheat allergens causing clinical allergy vary among populations. The diagnostic accuracy of conventional allergy tests such as skin prick test (SPT) and blood sIgE assays for wheat allergy is suboptimal, while the roles of newer diagnostic methods such as basophil activation test (BAT; based on functional IgE-crosslinking) remains poorly defined for this food allergy.
For wheat-dependent exercise-induced anaphylaxis (WDEIA), omega-5 gliadins and high-molecular-weight glutenin subunits were most often reported as major allergens. SPT and sIgE to wheat might be negative, and even sIgE to omega-5 gliadins were only positive in about 80% of these patients. BAT combined with florescence-activated cell sorting is a new approach to complement wheat-dependent exercise-induced anaphylaxis diagnosis. BAT-derived parameters such as the percentage of CD63+ or CD203c+ basophils have been shown to be sensitive biomarkers for wheat allergy. Expression of CD203c induced by purified native omega-5 gliadin provided the best power for discriminating between wheat allergic and tolerant subjects. On the other hand, there has not been any head-to-head comparison between BAT and conventional allergy tests for wheat allergy or evidence on the optimal stepwise algorithms with these allergy tests for diagnosing wheat allergy. Such unmet clinical need prompts our team to look for precision diagnostic approach to wheat allergy in children.
Unlike cow's milk and egg, many children with wheat allergy have persistent allergy into school-age. A large retrospective study from the United States found that about one-third of wheat allergic patients had persistent disease into adolescence. The standard of care for wheat allergy is strict avoidance and prompt treatment of allergic reactions upon accidental ingestion. However, complete wheat avoidance is difficult in real life as it is widely present in common foods such as cakes, noodles, pasta, bread and even seasoning soya sauce.
Food oral immunotherapy (OIT) is conventionally achieved in a long-enough duration that ultimately induces immunological tolerance of patients to oral intake of the allergenic food. The immunological changes resulted from OIT involved both innate and adaptive mechanisms that included reduced mediator release from mast cells and basophils, initial rise followed by decrease in food-specific IgE and increased food-specific IgG4, expansion and affinity maturation of specific memory B cells, and stimulation of regulatory T cells with release of IL-10 and IFN-gamma. Standard OIT protocols consist of three phases. Typically, patients start the first rush phase by eating a very small dose (equal to the eliciting dose from double-blind, placebo-controlled food challenge [DBPCFC]) of the testing food then incrementally for 6-8 doses per day. This phase carries a high risk of systemic reaction. At the end of this phase, patient will be advised about the safe starting dose for home administration. In the next build-up phase, patients will ingest increasing amount of food every 1-2 weeks until they reach the maintenance dose (usually one serving dose). They will maintain this dose for at least 1-2 years, after which be evaluated for outcomes of desensitization and tolerance (or otherwise called sustained unresponsiveness [SU]). Desensitization denotes a condition in which patients can tolerate maintenance dose while consuming food regularly whereas SU denotes ability to tolerate doses even when patients discontinue the regular dosing. There is limited evidence on the safest and most effective OIT protocol for wheat.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Care Provider, Investigator, Outcomes Assessor)
盲法说明
Research staff performing laboratory assays
入排标准
- 年龄范围
- 1 Year 至 17 Years(Child)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •First stage to diagnose immediate-type wheat allergy:
- •1-17 years old
- •History of adverse reactions within four hours after foods containing wheat or gluten
- •IgE sensitization to wheat by positive SPT or serum sIgE level
- •Parent give informed written consent to participate
- •Second stage to commence oral immunotherapy of wheat for 12 months:
- •Failed wheat double-blind, placebo-controlled food challenge (DBPCFC) under stage I
- •3-17 years old
- •Body weight more than 8 kg
- •IgE sensitization to wheat by positive SPT or serum sIgE level
- •Parent give informed written consent to participate
排除标准
- •First stage for diagnosis of immediate-type wheat allergy:
- •Eczema flare or severe allergic reactions within 4 weeks
- •Intake of antihistamines within 1 week
- •Systemic corticosteroid treatment within 4 weeks
- •Intravenous immunoglobulin, systemic immunosuppressive or biologic within 3 months
- •Inability to follow the requirements and expected procedure of DBPCFC
- •Second stage of wheat oral immunotherapy for 12 months:
- •History of severe anaphylaxis to wheat
- •Severe anaphylaxis during double-blind placebo-controlled wheat challenge from stage 1
- •Active medical conditions
- •Use of beta-blockers or angiotensin-converting enzyme inhibitors
- •Have received other food oral immunotherapy treatment within 12 months
- •Eczema flare or severe allergic reactions within 4 weeks;
- •Intake of antihistamines within 1 week
- •Systemic corticosteroid treatment within 4 weeks;
- •On Intravenous immunoglobulin, systemic immunosuppressive or biologic within 3 months
- •Inability to follow the requirements and protocol for wheat oral immunotherapy
结局指标
主要结局
Wheat-allergic patients who develop sustained unresponsiveness to wheat after oral immunotherapy
时间窗: 13 months
The occurrence of sustained unresponsiveness to wheat is detected at 1 month after discontinuation of oral immunotherapy by double-blind, placebo-controlled wheat challenge
次要结局
- Tolerability and safety between standard-dose and low-dose arms of wheat oral immunotherapy(12 months)
- Correlation among skin prick test (SPT), specific IgE level (sIgE) and basophil activation test (BAT) with crude wheat extract and wheat allergens and their diagnostic accuracy for wheat allergy(3 years)
- Stepwise diagnostic algorithms of different biomarkers for wheat allergy(3 years)
- Changes in different allergy biomarkers after low-dose oral immunotherapy and standard-dose oral immunotherapy for wheat(18 months)
- Treatment compliance to wheat oral immunotherapy intervention(12 months)
- Wheat-allergic patients who develop desensitization to wheat after oral immunotherapy(12 months)
研究者
Ting-fan Leung
Clinical Professor
Chinese University of Hong Kong
